Pharma: Clinic Roundup
Monday, June 25, 2012
Novo Nordisk A/S, of Bagsvaerd, Denmark, said its ultra-long-lasting insulin degludec significantly reduced the rate of hypoglycemia at night in adults with Type II diabetes, while obtaining equivalent improvement in glucose control compared with insulin glargine over a 52-week period.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.